中文摘要：

目的研究骨髓增生异常综合征（MDS）患者骨髓CD34＋CD38-CD123＋细胞信号转导和转录活化蛋白5（STAT5）磷酸化（P-STAT5）水平，初步探讨MDS患者骨髓原代细胞胞内与增殖有关的STAT5存在状态。方法采用流式细胞术分别检测36例MDS患者及14名正常对照者原代骨髓单个核细胞（BMMNC）在给予10U／m1EPO刺激前后CD34＋CD38CD123＋和CD34＋CD38CD123-细胞P．STAT5表达水平[以平均荧光强度（MFI）表示]。结果未加入EPO刺激的高、低危组患者CD34＋CD38-CD123＋细胞P—STAT5表达水平分别为173．05±102．78和113．71±67．22，明显高于CD34＋CD38-CD123-细胞（68．99±50．42和58．84±27．51，P值分别〈0．01和〈0．05）和正常对照组CD34＋CD38-CD123-细胞（63．06±21．06，P值分别〈0．01和〈0．05），MDS患者组与正常对照组CD34＋CD38-CD123-细胞P，STAT5表达水平比较差异无统计学意义（P〉0．05）；EPO刺激的高、低危组患者CD34＋CD38CD123＋细胞P—STAT5表达水平分别为239．45-．I-152．05和144．04±58．11，明显高于CD34＋CD38-CD123-细胞（64．21±23．43和68．41±25．10，P值均〈0．01）和正常对照组CD34＋CD38-CD123-细胞（75．21±27．02，P〈0．01），MDS患者组与正常对照组CD34＋CD38-CD123-细胞P—STAT5表达水平比较差异无统计学意义（P〉0．05）。EPO刺激后，高、低危组患者CD34＋CD38-CD123＋细胞P—STAT5表达水平的中位增高值分别为28．86和21．80，明显高于CD34＋CD38-CD123-细胞（5．50和7．42，P值分别〈0．01和〈0．05）和正常对照组CD34＋CD38-CD123-细胞（6．39，P值分别〈0．01和〈0．05）；EPO刺激前后MDS患者组与正常对照组CD34＋CD38-CD123细胞P—STAT5表达的增高水平比较差异无统计学意义（P〉0．05）；EPO刺激前后CD34＋CD38-CD123＋细胞P—STAT5表达水平及刺激后增高水平在高、低危组患者问差异无统计学意义（P值均〉0．05）。结论MDS患者

英文摘要：

Objective To investigate the expressions of STAT5 phosphorylation in CD34 ＋CD38- CD123 ＋ bone marrow cells of the patients with myelodysplastic syndromes （MDS） , and then evaluate the lev- el of activation of STATS associated with cell proliferation in MDS elone cells. Methods The bone marrow mononuclear cells （BMMNC） were extracted from 36 MDS patients and 14 normal controls. The mean fluorescence intensities （MFI） of phosphorylated STAT5 （ P-STAT5 ） in CD34 ＋ CD38 - CD123 ＋ and CD34 ＋ CD38- CD123- cells, with or without the stimulation of 10 U/ml EPO, were examined by flow cytometry （FCM）. Results Without stimulation, the P-STAT5 MFI in CD34 ＋ CD38 - CD123 ＋ cells of low/high risk MDS patients was 113.71 ± 67.22/173.05 ± 102.78, which was significantly higher than that of CD34 ＋ CD38 - CD123 - cells （58.84 ±27.51/68.99 ± 50.42, P 〈 0.01, P 〈 0.05 ） and the normal controls CD34 ＋ CD38 - CD123 - cells （63.06 ±21.06, P 〈0. 05 ）, there was no significant difference between the CD34 ＋ CD38-CD123- cells of MDS patients and the normal control CD34＋ CD38- CD123- cells; With the EPO stimulation, the P-STAT5 MFI in CD34 ＋ CD38 - CD123 ＋ cells of low/high risk MDS patients was 144.04 ± 58.11/239.45± 152.05, which was significantly higher than that of CD34 ＋ CD38 - CD123 - cells （68.41 ± 25,10/64.21 ± 23.43, P 〈 0.01 ） and the normal controls CD34 ＋ CD38 - CD123 - cells （ 75.21 ± 27.02, P 〈0.01 ） , there was no significant difference between the CD34 ＋ CD38 - CD123 - cells of MDS patients and the normal control CD34 ＋ CD38 - CD123 - cells; The P-STAT5 MFI in the CD34＋ CD38- CD123 ＋ cells of low/high risk MDS patients with or without EPO stimulation were 21.80/28.86, which was significantly high- er than that of CD34 ＋ CD38 - CD123 - cells （7.42/5.50, P 〈 0.01, P 〈 0.05 ） and the normal controls CD34＋ CD38- CD123- cells （6.39, P 〈 0.05）, there was no significant difference between the CD34＋ CD38- CD123- cells of